Literature DB >> 23958921

Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.

J Hillengass1, M-A Weber2, K Kilk2, K Listl2, B Wagner-Gund3, M Hillengass3, T Hielscher4, A Farid3, K Neben3, S Delorme5, O Landgren6, H Goldschmidt7.   

Abstract

Radiological skeletal survey or computed tomography are currently applied to assess bone diseases in patients with monoclonal plasma cell disorders. Whole-body magnetic resonance imaging (whole-body MRI) allows detecting the infiltration of clonal cells in nearly the whole bone marrow compartment even before bone destruction has occurred. Those MRI results (i.e., patterns of bone marrow infiltration) have been demonstrated to be of prognostic significance in patients with symptomatic as well as asymptomatic multiple myeloma. We have therefore analyzed the findings of whole-body MRI in 137 consecutive individuals with monoclonal gammopathy of undetermined significance (MGUS). A focal infiltration pattern was detected in 23.4% of patients. Presence and number of focal lesions as well as value of M-Protein were of independent prognostic significance for progression into a symptomatic disease requiring systemic treatment (P=0.02; P<0.0001 and P=0.0005, respectively). Lower homogeneous signal intensities in T1-weighted images were related to a physiologically higher bone marrow cellularity in younger individuals (P=0.002). We conclude that whole-body MRI identifies patients with focal accumulations of presumably monoclonal cells in bone marrow with prognostic impact concerning the risk of progression into symptomatic disease.

Entities:  

Mesh:

Year:  2013        PMID: 23958921     DOI: 10.1038/leu.2013.244

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  29 in total

1.  Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals.

Authors:  Jens Hillengass; Bram Stieltjes; Tobias Bäuerle; Fabienne McClanahan; Christiane Heiss; Thomas Hielscher; Barbara Wagner-Gund; Verena Habetler; Hartmut Goldschmidt; Heinz-Peter Schlemmer; Stefan Delorme; Christian M Zechmann
Journal:  Acta Radiol       Date:  2011-03-03       Impact factor: 1.990

2.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

3.  Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.

Authors:  A Stäbler; A Baur; R Bartl; R Munker; R Lamerz; M F Reiser
Journal:  AJR Am J Roentgenol       Date:  1996-10       Impact factor: 3.959

4.  Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.

Authors:  L A Moulopoulos; D Gika; A Anagnostopoulos; K Delasalle; D Weber; R Alexanian; M A Dimopoulos
Journal:  Ann Oncol       Date:  2005-08-08       Impact factor: 32.976

5.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

6.  Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome.

Authors:  B C Vande Berg; L Michaux; F E Lecouvet; M Labaisse; J Malghem; J Jamart; B E Maldague; A Ferrant; J L Michaux
Journal:  Radiology       Date:  1997-01       Impact factor: 11.105

7.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.

Authors:  Andrea Baur-Melnyk; Sonja Buhmann; Christoph Becker; Stefan Oswald Schoenberg; Nicola Lang; Reiner Bartl; Maximilian Ferdinand Reiser
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

9.  Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.

Authors:  Tobias Bäuerle; Jens Hillengass; Kerstin Fechtner; Christian M Zechmann; Lars Grenacher; Thomas M Moehler; Heiss Christiane; Barbara Wagner-Gund; Kai Neben; Hans-Ulrich Kauczor; Hartmut Goldschmidt; Stefan Delorme
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

10.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

View more
  17 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  Automated MR-based lung volume segmentation in population-based whole-body MR imaging: correlation with clinical characteristics, pulmonary function testing and obstructive lung disease.

Authors:  Jan Mueller; Stefan Karrasch; Roberto Lorbeer; Tatyana Ivanovska; Andreas Pomschar; Wolfgang G Kunz; Ricarda von Krüchten; Annette Peters; Fabian Bamberg; Holger Schulz; Christopher L Schlett
Journal:  Eur Radiol       Date:  2018-08-27       Impact factor: 5.315

Review 3.  Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis.

Authors:  So-Yeon Lee; Hyun-Jung Kim; Yu Ri Shin; Hee-Jin Park; Yun-Gyoo Lee; Suk Joong Oh
Journal:  Eur Radiol       Date:  2016-09-05       Impact factor: 5.315

Review 4.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

5.  [Radiological diagnostics of multiple myeloma].

Authors:  M D'Anastasi; S Grandl; M F Reiser; A Baur-Melnyk
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

6.  Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Authors:  Manisha Bhutani; Baris Turkbey; Esther Tan; Neha Korde; Mary Kwok; Elisabet E Manasanch; Nishant Tageja; Sham Mailankody; Mark Roschewski; Marcia Mulquin; Ashley Carpenter; Elizabeth Lamping; Alex R Minter; Brendan M Weiss; Esther Mena; Liza Lindenberg; Katherine R Calvo; Irina Maric; Saad Z Usmani; Peter L Choyke; Karen Kurdziel; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2016-04-07

Review 7.  Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.

Authors:  Srinath Sundararajan; Abhijeet Kumar; Neha Korde; Amit Agarwal
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

8.  Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

Authors:  Rashid Khan; Madhav Dhodapkar; Adam Rosenthal; Christoph Heuck; Xenofon Papanikolaou; Pingping Qu; Frits van Rhee; Maurizio Zangari; Yogesh Jethava; Joshua Epstein; Shmuel Yaccoby; Antje Hoering; John Crowley; Nathan Petty; Clyde Bailey; Gareth Morgan; Bart Barlogie
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

9.  Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

Authors:  James E McDonald; Marcus M Kessler; Michael W Gardner; Amy F Buros; James A Ntambi; Sarah Waheed; Frits van Rhee; Maurizio Zangari; Christoph J Heuck; Nathan Petty; Carolina Schinke; Sharmilan Thanendrarajan; Alan Mitchell; Antje Hoering; Bart Barlogie; Gareth J Morgan; Faith E Davies
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

Review 10.  Oncologist perspective: role of imaging in myeloma.

Authors:  Yael N Shapiro; Elizabeth K O'Donnell
Journal:  Skeletal Radiol       Date:  2021-07-17       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.